This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LeadingBiotech: Cancer Advance
March 5, 2020
Koch Institute for Integrative Cancer Research at MITCambridge, MA

Elly Barry, MD, MMSc
Senior Director | Pediatric Oncology Therapeutic Area Clinician Leader at Pfizer


Elly Barry is a board-certified pediatrician and pediatric hematologist/oncologist, currently overseeing pediatric oncology clinical development at Pfizer, and responsible for developing and implementing strategy and deliverables related to pediatric development plans. While at Pfizer, she has contributed to the development of PIPs/PPSRs across a number of compounds, including bosutinib, gemtuzumab ozogamicin, inotuzumab ozogamizin, palbociclib and sunitinib. She is the Head of the Pediatric Oncology Leadership Team at Pfizer, and a member of Pfizer’s Pediatric Council. Elly serves on the Industry Advisory Councils of CureSearch and the Ronald McDonald House-NY. She is a member of the ACCELERATE Platform Steering Committee and will Co-Chair the Pediatrics Specialty Committee of BIO (Biotechnology Innovation Organization) in 2020.

Elly received her MD degree from Yale University School of Medicine in New Haven, before completing residency training in pediatrics at Tufts-New England Medical Center/Floating Hospital for Children in Boston, and fellowship training in pediatric hematology/oncology at Boston Children’s Hospital/Dana-Farber Cancer Institute in Boston. She remained on staff at DFCI as an Instructor in Pediatric Hematology/Oncology and Bone Marrow Transplantation, while obtaining a Masters in Medical Science degree from Harvard Medical School. Her previous industry roles at Genzyme, Millennium and Pfizer have focused on the early and late development of drugs for hematologic malignancies, breast, renal, and prostate cancers.

Agenda Sessions

  • Pediatric Regulatory Update – Impacts on Drug Development